scholarly journals Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin’s lymphoma

2020 ◽  
Vol 60 (2) ◽  
pp. 37-40
Author(s):  
Akiko Fukunaga ◽  
Yoshio Okamoto ◽  
Sho Shibata ◽  
Shojiro Inano ◽  
Yoko Takiuchi ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Heavily Pretreated

scholarly journals ESHAP as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma: Taiwan Experience

1999 ◽  
Vol 29 (1) ◽  
pp. 33-37 ◽  
Author(s):  
W.-S. Wang ◽  
T.-J. Chiou ◽  
J.-H. Liu ◽  
F. S. Fan ◽  
C.-C. Yen ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments

1988 ◽  
Vol 74 (4) ◽  
pp. 433-438 ◽  
Author(s):  
Umberto Tirelli ◽  
Vittorina Zagonel ◽  
Rachele Volpe ◽  
Mauro G. Trovo ◽  
Antonino Carbone
Keyword(s):  
Elderly Patients ◽  
Hodgkin’S Lymphoma ◽  
Randomized Trials ◽  
Survival Rates ◽  
The Elderly ◽  
Hodgkin's Lymphoma ◽  
Severe Toxicity ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Significant Difference

The outcome of 70 elderly patients aged 65 years or more (median, 71 years) with non-Hodgkin's lymphoma (NHL) treated between 1973 and 1981 with aggressive (AM) or conservative modalities (CM) was retrospectively evaluated. A significantly higher incidence of lethal and severe toxicity was observed in patients treated with AM than in those treated with CM (32 % vs 3 %, p < 0.01), with 10 % treatment related deaths in the AM group. Only 56 % of the deaths were attributed to NHL; other major causes were treatment-related deaths, infection and cardiac diseases. No significant difference in response and survival was found between AM and CM groups (complete remission rates were 35 % vs 42 %, and 10 year survival rates were 31 % vs 19 %, respectively), but the prevalence of stages III-IV in patients treated with AM makes these results meaningless. Prospective randomized trials with AM vs CM are clearly needed in elderly patients with advanced unfavorable NHL.

Sign in / Sign up

Export Citation Format

Share Document